VIEW Reaction to new Novo Nordisk CEO, profit warning
Here are some reactions from market analysts and investors:
MARKUS MANNS, A PORTFOLIO MANAGER AT MUTUAL FUNDS FIRM UNION INVESTMENT AND A SHAREHOLDER IN THE COMPANY:
"While most people had expected Novo to just trim the top end of the guidance, the magnitude of the guidance cut is a shocker. Novo's problems are much deeper than just compunded Wegovy in the U.S. and extend to the international Wegovy franchise and even to Ozempic in diabetes. Novo has underestimated the self pay market in obesity and just recently started to focus on this important patient segment."
JEFFERIES ANALYST BENJAMIN JACKSON ON NEW CEO:
"We are surprised by the appointment of Mike Doustdar as CEO, with feedback suggesting an external candidate may have been preferred."
J.P.MORGAN ANALYSTS ON THE PROFIT WARNING:
"Lowered guidance (is) a reflection of growth expectations in H2'25 for both Wegovy and Ozempic."
CITI ANALYSTS ON THE PROFIT WARNING:
"We caution against over-reading into Novo's assessment, given tirzepatide's script strength pre-July 1st has been robust and Lilly may have had a more conservative outlook on expectations when giving its own 2025 guidance. Thus, we remain buyers on weakness."
ANGELO MEDA, PORTFOLIO MANAGER AND HEAD OF EQUITIES AT BANOR SIM IN MILAN:
"The biggest concern is the illegal channel siphoning away market share—something that's hard to quantify. Rebuilding trust will take time."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
4 hours ago
- Powys County Times
Concern over weight gain after ‘skinny jabs'
Health chiefs have raised concerns about people regaining weight after using Wegovy and Mounjaro, saying that patients coming off the drugs should be given support to help prevent them piling on the pounds again. Research shows that many people regain weight after stopping treatment if they are not supported, the National Institute for Health and Care Excellence (Nice) said. The health watchdog said that people coming off the drugs should be offered 'structured advice and follow-up support' to help prevent weight gain. The guidance is for people who are offered the treatments through the NHS. An estimated 1.5 million people are taking weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support after they have finished their treatment. Around 240,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. Little swaps can make tasty, healthy changes. For lots of tips and support to eat better visit: — NHS Blackpool Teaching Hospitals 💙🌈 (@BlackpoolHosp) April 12, 2025 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'
Scottish Sun
5 hours ago
- Scottish Sun
New ‘crucial' fat jabs guidance issued for the NHS – are you affected?
Hundreds of thousands of Brits take the injections JABS UPDATE New 'crucial' fat jabs guidance issued for the NHS – are you affected? Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FAT jabs are not a 'quick fix' and patients must be followed up for at least a year to keep the weight off, the NHS watchdog has warned. The National Institute for Health and Care Excellence (Nice) told clinics to offer more follow-up appointments and aftercare. Sign up for Scottish Sun newsletter Sign up 1 2RD5P46 photo of Mounjaro Weight Loss Pen Credit: Alamy More than 1.5million Brits are thought to be taking weight loss injections such as Wegovy and Mounjaro. Most are on private prescriptions where many do not receive help with diet and exercise alongside the medication. Studies suggest people start re-gaining weight within two months of stopping the jabs, and often put it all back on within two years. Professor Jonathan Benger, chief medical officer at Nice, said: 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme. 'The transition period after treatment is crucial. 'People need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care.' Check-ups to prevent weight regain The standard issued to NHS clinics tells them how to look after patients taking weight loss injections. They must get action plans for staying healthy at home and at work, have regular check-ins and have community support available. Dr Rebecca Payne, head of standards at Nice, said: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines can help prevent weight regain.' Sun Health Explainer: Fat jabs Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
BBC News
5 hours ago
- BBC News
Obesity jabs: Help needed to keep weight off after stopping them
People coming off obesity jabs like Wegovy and Mounjaro should have check-ups for at least a year to make sure they don't pile weight back on, new advice for the NHS not uncommon for people to regain most of what they shed once they stop treatment, experience shows. The guidance, from health assessment body NICE, warns weight management is a long-term journey, not a short-term may need extra support and a plan for how to stay at their new weight, such as eating healthily and hitting the gym or going for walks, it says. In England alone, obesity affects around one in four estimated 1.5 million people are on weight loss jabs in the UK, but the vast majority are paying for them privately so will not be eligible for NHS support as they come off the (semaglutide) is already available on the NHS on prescription, but only to those most in need (with health problems due to their weight and a high BMI) for a period of two 240,000 people are expected to be offered Mounjaro (tirzepatide) over the next three years. There's currently no specified time limit for being prescribed the drugs help reduce appetite and can lead to life-changing weight loss. They are prescribed alongside programmes that support healthy weight loss through changes to diet and physical a Wegovy drug trial, patients regained around two-thirds of their original weight once they came off the injections. It's a similar story for those on advice from NICE, the National Institute for Health and Care Excellence, encourages patients to build long-term behavioural habits, use self-monitoring tools, and draw on wider support "from online communities to family-led interventions and local activities."Prof Jonathan Benger from NICE said: "Successful weight management doesn't end when medication stops or when someone completes a behavioural programme."We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made."Prof Kamila Hawthorn from the Royal College of GPs said: "There is no one-size fits all approach to tackling obesity - what works for one patient will likely not work for another."We also need to see a greater focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later."Obesity can cause people difficulties in their daily lives, and put them at more risk of serious health problems, such as heart disease, type 2 diabetes, and some types of cancer.
